Hair loss associated with cancer treatment — primarily chemotherapy-induced alopecia — is one of the most distressing side effects patients report, and one where honest information about what to expect, when to expect recovery, and what options exist for persistent loss makes a meaningful difference.
Chemotherapy-induced hair loss occurs because chemotherapy drugs target rapidly dividing cells — which includes cancer cells but also includes hair follicle cells in the anagen phase. Most chemotherapy agents cause significant diffuse hair loss within two to four weeks of starting treatment, affecting the scalp, eyebrows, lashes, and body hair to varying degrees depending on the specific regimen.
The good news for most patients is that chemotherapy-induced hair loss is temporary. Follicles are not destroyed — they are forced into a resting phase. Hair regrowth typically begins two to three months after the end of chemotherapy. It may initially grow back with a different texture or wave pattern (often called chemo curl) and possibly a slightly different colour. Most patients see their hair return to its pre-treatment characteristics within one to two years.
A minority of patients — more commonly with specific drugs including docetaxel and busulfan at high doses — experience persistent or permanent hair loss. This is called persistent chemotherapy-induced alopecia (pCIA) and is an increasingly recognised condition. Patients who have not seen significant regrowth twelve to eighteen months after completing treatment should discuss this with an oncologist or dermatologist.
Hair transplant surgery for pCIA is possible for eligible patients in complete remission. The assessment includes oncological clearance, confirmation of stable hair loss, and evaluation of donor zone viability.
Related reading
